EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations

Ann Hematol. 2014 Jan;93(1):163-4. doi: 10.1007/s00277-013-1974-z. Epub 2013 Nov 29.

Authors

Massimiliano Bonifacio¹, Gianni Binotto, Elisabetta Calistri, Elena Maino, Mario Tiribelli; Gruppo Triveneto LMC

Affiliation

¹ Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.

PMID: 24292539
DOI: 10.1007/s00277-013-1974-z

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Benzamides / therapeutic use*
Female
Fusion Proteins, bcr-abl / antagonists & inhibitors
Fusion Proteins, bcr-abl / blood
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Piperazines / therapeutic use*
Practice Guidelines as Topic
Prognosis
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / therapeutic use*
Retrospective Studies
Risk Assessment
Severity of Illness Index*
Treatment Outcome
Young Adult

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl